This page shows what was measured, who it was measured in, and what that does not settle.
What Eslicarbazepine does in the body
Partial-onset seizures
From the FDA-approved label: Eslicarbazepine acetate tablets is extensively converted to eslicarbazepine, which is considered to be responsible for therapeutic effects in humans. The precise mechanism(s) by which eslicarbazepine exerts anticonvulsant activity is unknown but is thought to involve inhibition of voltage-gated sodium channels.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
RNAWiki has not recorded a supervision or regulatory status for this substance.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · S5VXA428R4 · read 2026-08-29
Its recorded molecular formula is C17H16N2O3, weighing 296.33 g/mol.
US prescribing information · 22f29752-614f-caaf-b595-9deae8a3e3ff · read 2026-08-30
Where each sentence above came from
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
No statement of the main limit is recorded.
The four opening statements run to 60 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Biomarker
A biomarker is a number from a test that stands in for something about health.
A picture of it, and where the picture fails
A biomarker is like a fuel gauge.
Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.
What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.
A measurable indicator used as a substitute for a clinical outcome of interest.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
What happened in people◇Read from sources, not yet reviewed
What was measured, goal by goal
One row for each goal a registered study measured something for. One column for each kind of thing that could be measured.
Registered studies list 33 outcome measures that RNAWiki could read. A registered study says what someone planned to measure. It does not say what they found. 0 of the matched studies tested this substance, and 0 posted a result.
There is no single score. A strong test result and a weak life result are different facts.
Goals down the side, kinds of measurement across the top. Each cell says what kind of thing was registered, not what was found.
Goal
Life outcome
What a body can do
How a person feels
A test result
A step in the body
Harms
How long
Who was studied
Pain
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
…Waiting for a reviewer1 registered symptom measure.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Focus
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Healthy ageing
…Waiting for a reviewer1 registered study measure of this kind. No reviewed result yet.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Which registered measures put each goal on this table
Pain
pain from baseline to endpoint in mean pain
Focus
power of attention to the end of the double blind period
Healthy ageing
mortality
Sorted by fixed word lists, version v1. A name the rules do not recognise stays unsorted rather than moving to the nearest column.
What each mark on this table means
∅ Nothing in the sources checked
No registered study lists a life outcome for this goal.
… Waiting for a reviewer
1 registered symptom measure.
— Not recorded
Harms were not a registered measure for this goal.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
The primary efficacy variable will be the proportion of subjects in the PP set who are seizure free for the entire 26-week Evaluation Period at the last received dose level.
✗ The study did not show it
Who was studied
NCT01162460
How many people
815
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Seizure Frequency Over the 12-week Maintenance Period.
✗ The study did not show it
Who was studied
NCT00988429
How many people
653
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Change in Mean Pain (NRPS) From Baseline to Endpoint in Mean Pain
✗ The study did not show it
Who was studied
NCT00981227
How many people
567
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Change From Baseline to Endpoint in Mean Pain, Scored Daily on a on an 11-point (0-10) Numeric Rating Pain Scale (NRPS), Where 0 = no Pain and 10 = Worst Possible Pain
✗ The study did not show it
Who was studied
NCT00980746
How many people
557
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Absolute Change From Baseline to Endpoint in Mean Pain
✗ The study did not show it
Who was studied
NCT01820585
How many people
528
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Absolute Change From Baseline in the Frequency of Migraine Attacks
✗ The study did not show it
Who was studied
NCT01820559
How many people
452
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.1 registered measure of this kind. No reviewed result.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
■Symptoms and quality of lifeEvidence recorded. Pain, tiredness, mood, sleep, as the person rated it.1 registered measure of this kind.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.5 registered measures of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
□AnimalsNo evidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.No animal record is stored.
□Cells in a dishNo evidence recorded. Cells or chemistry on a bench, far from a whole body.No cell or bench record is stored.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
pain from baseline to endpoint in mean pain
Measured
Things only a test, a scale or a device shows.
cmax maximum observed plasma concentration
maximum drug concentration
area under the plasma concentration versus time curve auc
cmax the maximum plasma concentration
maximum observed plasma concentration
Meaningful
Things that change how a life goes, not only a number.
mortality
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (26)
auc0 t auc from time zero to the last sampling time
number and of treatment emergent adverse events
part i seizure frequency
part ii n of treatment emergent adverse events
seizure frequency
simvastatin cmax
simvastatin tmax
simvastatin auc0 t
simvastatin auc0
responder rate
reported adverse events
power of attention to the end of the double blind period
seizure reduction
seizure severity
time to onset of treatment effect
seizure free
changes in hrqol
all drop outs
drop outs due to ae
adverse events
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What it would be like to take◇Read from sources, not yet reviewed
How long anything takes
Nine different lengths of time that get confused with each other. None of them is worked out from another.
Before anything is noticed.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before a test result moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before performance moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
How long the result was watched.No finished study window is recorded for a study that tested this substance.
How long people took it.How long people actually took it is not stored. The study window is not the same thing.
How long people were followed.Follow-up length is not stored separately. It is never read off the study window, which would be a different thing.
How fast the body clears it. 13 to 20 hours hours
Read from the label, which states: “The apparent half-life of eslicarbazepine in plasma was 13 to 20 hours in adult epilepsy patients.”
How long effects linger.RNAWiki does not store this separately, and never works it out from another figure on this page.
Beyond the studies. Nothing is recorded about the long term.
The longest finished study sets the edge of what anyone measured.
A study window is not how long people took it, and neither is how long they were followed. Where RNAWiki holds only one of the three, it shows one.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
Eslicarbazepine acetate tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older. Eslicarbazepine acetate tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older. ( 1 )
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “Safety and effectiveness in pediatric patients below the age of 4 years have not been established.”
US prescribing information · 22f29752-614f-caaf-b595-9deae8a3e3ff · read 2026-08-30
On older people, the label states: “The pharmacokinetics of eslicarbazepine acetate were evaluated in elderly healthy subjects (N = 12) (Figure 1).”
US prescribing information · 22f29752-614f-caaf-b595-9deae8a3e3ff · read 2026-08-30
On people who are pregnant, the label states: “Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to AEDs, such as eslicarbazepine acetate, during pregnancy.”
US prescribing information · 22f29752-614f-caaf-b595-9deae8a3e3ff · read 2026-08-30
On people who are breastfeeding, the label states: “Eslicarbazepine is present in human milk.”
US prescribing information · 22f29752-614f-caaf-b595-9deae8a3e3ff · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
RNAWiki has not recorded a supervision or regulatory status for this substance.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
No register row and no identity class settled the question.
No source is stored against this line.
What is in the pack
Sold as tablet, given by the oral route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Reports sent to a regulator
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Eslicarbazepine appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 52 reaction mentions were counted. One report can name several reactions.
The recorded terms (10)
seizure — 9 reaction mentions
abortion spontaneous — 7 reaction mentions
drug intolerance — 6 reaction mentions
multiple-drug resistance — 6 reaction mentions
dystonia — 5 reaction mentions
drug reaction with eosinophilia and systemic symptoms — 4 reaction mentions
dysarthria — 4 reaction mentions
irritability — 4 reaction mentions
salivary hypersecretion — 4 reaction mentions
cerebellar ataxia — 3 reaction mentions
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
57 products list this as an active ingredient in the United States drug directory. 57 of them contain it and nothing else.
FDA National Drug Code directory · 51508-014 · read 2026-08-29
They are sold as powder and tablet, taken oral.
FDA National Drug Code directory · 51508-014 · read 2026-08-29
The regulator's established pharmacologic class for it is cytochrome p450 2c19 inhibitors [moa], cytochrome p450 3a4 inducers [moa] and decreased central nervous system disorganized electrical activity [pe].
FDA National Drug Code directory · 51508-014 · read 2026-08-29
10 published labels name it as an active ingredient. 10 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 22f29752-614f-caaf-b595-9deae8a3e3ff · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 22f29752-614f-caaf-b595-9deae8a3e3ff · read 2026-08-29
Eslicarbazepine Acetate is oral at 3 DOSAGE FORMS AND STRENGTHS Eslicarbazepine acetate tablets are available in the following shapes and color: 200 mg tablets: White to off-white, oval, biconvex tablet with functional scoring, engraved “E” score “S” on…, recorded as fda label in effect 2025-04-08 in the United States.
US prescribing information · 22f29752-614f-caaf-b595-9deae8a3e3ff · read 2026-08-30
Recorded price in US: 1.58268–2.78385 USD per one unit as the pricing file counts it — a tablet, capsule, patch or single item, across 28 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..
Recorded source · 2026-08-26 · read 2026-08-28
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
RNAWiki could not confidently classify this substance, so no self-experiment plan is offered.
Questions worth asking
Which of the trials of Eslicarbazepine studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Eslicarbazepine are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
How many documents were read
10 documents were read for this substance.
RNAWiki source record
10 of them state the same halfLife, and they agree.
RNAWiki source record
10 of them state the same tMax, and they agree.
RNAWiki source record
10 of them state the same volumeOfDistribution, and they agree.
RNAWiki source record
Where else this substance is registered
FDA substance identifier (UNII)
S5VXA428R4
CAS registry number
104746-04-5
PubChem compound
9881504
ChEMBL
CHEMBL315985
WHO international nonproprietary name list entry
8403
RxNorm concept
1482502
EMA substance identifier
100000091741
DrugBank
DB14575
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Written into the record, not signed off.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✗ Not passed
Safety mode resolved
No register row and no identity class settled the question.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
10 approved applications cover products containing this substance. The earliest was NDA022416, approved 20131108 to SUMITOMO PHARMA AM.
This order is fixed in code and does not count clicks or time on the page.
What is not here
5 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
The path through the body — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (12)
Q1
What did Eslicarbazepine's largest trial (6498 people) and its longest (9.7 years) measure?
6498 people in Eslicarbazepine's largest registered study, 9.7 years in its longest registered window, measuring Mortality. ClinicalTrials.gov · 2026-09-01
13 phase1, 12 phase3, 9 phase2, 4 na or unstated, 2 phase4; NCT00988156; 2017-08-24. Last human test completed 2019, NCT03116828.
Interpretation These counts include studies where Eslicarbazepine was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase1
13
phase3
12
phase2
9
na or unstated
4
phase4
2
Last recorded human testNCT03116828
2019-06-06
recorded 2026-09-01 · last checked 2026-09-04
Q2
Eslicarbazepine was tested only in human — what did it show?
"Due to a slow recruitment rate"; 3 of 40 registered studies
Show the evidence
Trial
NCT01824602
terminated; "Due to a slow recruitment rate"
NCT01878578
terminated; "prematurely terminated due to impossibility of recruiting the planned number of patients by the study centre."
NCT03108729
withdrawn; "The study was not withdrawn for safety reasons. The sponsor received approval for the treatment of partial-onset seizures in patients 4 years of age and older"
recorded 2026-09-01 · last checked 2026-09-04
Q4
Human studies of Eslicarbazepine used Eslicarbazepine acetate 1600 mg — over how long?
4 recorded entries; human; also "Eslicarbazepine acetate 1200 mg", "Eslicarbazepine acetate 1800 mg", "Eslicarbazepine acetate 600 mg"
Show the evidence
human
NCT01091662
Eslicarbazepine acetate 1600 mg
NCT01091662
Eslicarbazepine acetate 1200 mg
NCT01824602
Eslicarbazepine acetate 1800 mg
NCT01824602
Eslicarbazepine acetate 600 mg
recorded 2026-09-01 · last checked 2026-09-04
Q5
Eslicarbazepine's half-life is 13 to 20 hours — which schedules were studied?
13 to 20 hours, the half-life Eslicarbazepine's label states. openfda-label · 2067fb77-9657-44da-b430-02e8a4efacb5 · 2026-08-30
Show the evidence
half life
13 to 20 hours hours; The apparent half-life of eslicarbazepine in plasma was 13 to 20 hours in adult epilepsy patients.
bioavailability
Eslicarbazepine is highly bioavailable, because the amount of eslicarbazepine and glucuronide metabolites recovered in urine corresponded to more than 90% of an eslicarbazepine acetate dose.
metabolism
Absorption, Distribution, Metabolism, and Excretion Absorption Eslicarbazepine acetate is mostly undetectable (0.01% of the systemic exposure) after oral administration.
recorded 2026-08-30 · last checked 2026-09-04
Q6
Could one person measure Eslicarbazepine's effect on auc0 t auc from time zero to the last sampling time?
Auc0 t auc from time zero to the last sampling time: measured in Eslicarbazepine's trials.
auc0 t auc from time zero to the last sampling time is the recorded endpoint.
Show the evidence
biomarkers
auc0 t auc from time zero to the last sampling time; 2026-09-01
number and of treatment emergent adverse events; 2026-09-01
part i seizure frequency; 2026-09-01
part ii n of treatment emergent adverse events; 2026-09-01
seizure frequency; 2026-09-01
cmax maximum observed plasma concentration; 2026-09-01
14 more recorded rows
biomarkers
pain from baseline to endpoint in mean pain; 2026-09-01
biomarkers
simvastatin cmax; 2026-09-01
biomarkers
simvastatin tmax; 2026-09-01
biomarkers
simvastatin auc0 t; 2026-09-01
biomarkers
simvastatin auc0; 2026-09-01
biomarkers
responder rate; 2026-09-01
biomarkers
reported adverse events; 2026-09-01
biomarkers
power of attention to the end of the double blind period; 2026-09-01
biomarkers
seizure reduction; 2026-09-01
biomarkers
seizure severity; 2026-09-01
biomarkers
time to onset of treatment effect; 2026-09-01
biomarkers
seizure free; 2026-09-01
biomarkers
changes in hrqol; 2026-09-01
biomarkers
all drop outs; 2026-09-01
half life
2026-09-04; halfLife; hours; 13 to 20 hours; 2026-08-30
human trials at or under30
11
smallest human trial
0; NCT03108729; PHASE3; the smallest recorded human enrolment at or below 30; the registry states no direction of its result; WITHDRAWN
Q7
Which of adverse events, adverse events leading to discontinuation and adverse events reported did Eslicarbazepine's trials measure?
adverse events, adverse events leading to discontinuation and adverse events reported lead 33 outcome terms across Eslicarbazepine's trials. ClinicalTrials.gov · 2026-09-01
Interpretation part ii n of treatment emergent adverse events, seizure frequency, cmax maximum observed plasma concentration, pain from baseline to endpoint in mean pain, simvastatin cmax and simvastatin tmax follow.
Show the evidence
auc0 t auc from time zero to the last sampling time
1
number and of treatment emergent adverse events
1
part i seizure frequency
1
part ii n of treatment emergent adverse events
1
seizure frequency
1
cmax maximum observed plasma concentration
1
14 more recorded rows
pain from baseline to endpoint in mean pain
1
simvastatin cmax
1
simvastatin tmax
1
simvastatin auc0 t
1
simvastatin auc0
1
responder rate
1
reported adverse events
1
power of attention to the end of the double blind period
1
seizure reduction
1
seizure severity
1
time to onset of treatment effect
1
seizure free
1
changes in hrqol
1
all drop outs
1
recorded 2026-09-01 · last checked 2026-09-04
Q8
What will the one ongoing trial of Eslicarbazepine report, and when?
"Prospective Study of Eslicarbazepine in Adults With Focal-Onset Seizures"; n 1500; "Change in Seizure Frequency"; 2026-12-31
recorded 2026-09-01 · last checked 2026-09-04
Q9
Which 5 trials of Eslicarbazepine posted no result?
Posted no result
5 of 5 completed trials
Registrations
NCT02283801, NCT01587339, NCT01830400, NCT01162460 and NCT03116321
Completion dates
oldest 2007-01; newest 2017-01-05
Show the evidence
Trial
NCT02283801
2007-01
NCT01587339
2011-07
NCT01830400
2014-06
NCT01162460
2016-09
NCT03116321
2017-01-05
Q10
At the median, Eslicarbazepine's trials enrolled 103 people — anything larger?
Median enrolment
103
Largest enrolment
6498
Registered trials counted
40
Q11
What do 52 spontaneous reports say about Eslicarbazepine — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Eslicarbazepine appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 52 reaction mentions were counted: seizure 9; abortion spontaneous 7; drug intolerance 6; multiple-drug resistance 6. open-targets-adr · CHEMBL315985 · 2026-06-24
Show the evidence
seizure
9
abortion spontaneous
7
drug intolerance
6
multiple-drug resistance
6
dystonia
5
drug reaction with eosinophilia and systemic symptoms
4
4 more recorded rows
dysarthria
4
irritability
4
salivary hypersecretion
4
cerebellar ataxia
3
recorded 2026-06-24 · last checked 2026-09-04
Q12
Eslicarbazepine and CYP1A2, CYP2A6 and CYP2B6: shared by which compounds?
CYP1A2, CYP2A6 and CYP2B6 appear in Eslicarbazepine's recorded interaction sentences, 7 in all. openfda-label+europepmc · 2026-08-30
Interpretation pharmacokinetics
Show the evidence
CYP1A2pharmacokinetics
In in vitro studies in human liver microsomes, eslicarbazepine had no clinically relevant inhibitory effect on the activity of CYP1A2, CYP2A6, CYP2B6, CYP2D6, CYP2E1, and CYP3A4, and only a moderate inhibitory effect on CYP2C19.
CYP2A6pharmacokinetics
In in vitro studies in human liver microsomes, eslicarbazepine had no clinically relevant inhibitory effect on the activity of CYP1A2, CYP2A6, CYP2B6, CYP2D6, CYP2E1, and CYP3A4, and only a moderate inhibitory effect on CYP2C19.
CYP2B6pharmacokinetics
In in vitro studies in human liver microsomes, eslicarbazepine had no clinically relevant inhibitory effect on the activity of CYP1A2, CYP2A6, CYP2B6, CYP2D6, CYP2E1, and CYP3A4, and only a moderate inhibitory effect on CYP2C19.
CYP2C19pharmacokinetics
In in vitro studies in human liver microsomes, eslicarbazepine had no clinically relevant inhibitory effect on the activity of CYP1A2, CYP2A6, CYP2B6, CYP2D6, CYP2E1, and CYP3A4, and only a moderate inhibitory effect on CYP2C19.
CYP2D6pharmacokinetics
In in vitro studies in human liver microsomes, eslicarbazepine had no clinically relevant inhibitory effect on the activity of CYP1A2, CYP2A6, CYP2B6, CYP2D6, CYP2E1, and CYP3A4, and only a moderate inhibitory effect on CYP2C19.
CYP2E1pharmacokinetics
In in vitro studies in human liver microsomes, eslicarbazepine had no clinically relevant inhibitory effect on the activity of CYP1A2, CYP2A6, CYP2B6, CYP2D6, CYP2E1, and CYP3A4, and only a moderate inhibitory effect on CYP2C19.
1 more recorded row
CYP3A4pharmacokinetics
In in vitro studies in human liver microsomes, eslicarbazepine had no clinically relevant inhibitory effect on the activity of CYP1A2, CYP2A6, CYP2B6, CYP2D6, CYP2E1, and CYP3A4, and only a moderate inhibitory effect on CYP2C19.
recorded 2026-08-30 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 9 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.